Clinical Research Management announced it has been awarded a new, 5-year, $97MM research support contract titled Support for Military Medical Research for the Soldier (SMMRS) to be performed at the Walter Reed Army Institute of Research (WRAIR). The United States Army Medical Research Acquisition Activity (USAMRAA) awarded the contract to ClinicalRM. USAMRAA is both the contracting element of the US Army Medical Research and Materiel Command (USAMRMC) and the provider of support to the Command headquarters and its worldwide network of laboratories and medical logistics organizations.
Through the course of the contract, ClincalRM will provide support for WRAIR’s goal of improving both national and international efforts to develop drugs, vaccines and associated products to address diseases of strategic interest to the United States Military and to develop products to enhance warfighter resilience, and reduce and mitigate the impact of brain injury and combat stress.
“We are very proud of the support our company currently provides to WRAIR which makes this award especially important. It is a testament to the value we bring to critical research that supports the warfighter and our country,” said Victoria Tifft, founder and CEO of ClinicalRM.
For 18 years, ClinicalRM has proven itself as a trusted partner to the US Armed Forces providing basic and applied research, clinical trials, and regulatory approval for a wide variety of agents. The SMMRS contract start date is July 1, 2011.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.